L3VLUP
ProSign in

NVST · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

NVSTLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • NVST
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterNVSTLLY
Q3 20209 holders, $873m33 holders, $14.1bn
Q4 202011 holders, $1.4bn29 holders, $17.3bn
Q1 202113 holders, $2.4bn24 holders, $23.0bn
Q2 202116 holders, $2.1bn24 holders, $27.8bn
Q3 20219 holders, $1.4bn31 holders, $29.9bn
Q4 20217 holders, $1.6bn31 holders, $34.7bn
Q1 202210 holders, $2.3bn24 holders, $35.3bn
Q2 20229 holders, $1.8bn33 holders, $42.7bn
Q3 202211 holders, $1.4bn31 holders, $43.4bn
Q4 20229 holders, $812m31 holders, $46.6bn
Q1 202311 holders, $1.2bn33 holders, $44.3bn
Q2 202311 holders, $868m37 holders, $59.6bn
Q3 20239 holders, $694m44 holders, $67.6bn
Q4 202312 holders, $714m45 holders, $73.6bn
Q1 20249 holders, $393m41 holders, $95.3bn
Q2 20244 holders, $248m43 holders, $110bn
Q3 20244 holders, $312m45 holders, $107bn
Q4 20244 holders, $301m46 holders, $93.9bn
Q1 20254 holders, $263m42 holders, $98.4bn
Q2 20256 holders, $432m43 holders, $93.2bn
Q3 20255 holders, $359m39 holders, $86.7bn
Q4 20255 holders, $339m41 holders, $123bn
Q1 20268 holders, $392m39 holders, $106bn
Q2 20269 holders, $577m44 holders, $132bn
NVST

Envista Holdings Corporation

Holders
12
Reported value
$714m
Buyers
7
Sellers
6

Breadth +1 among 93 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
LLY

Eli Lilly & Co

Holders
45
Reported value
$73.6bn
Buyers
27
Sellers
21

Breadth +6 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2023

Among the 47 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only NVST (2)

Caxton Associates LLP, Harris Associates LP

Only LLY (35)

Acadian Asset Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Maverick Capital Ltd, Millennium Management LLC, Moore Capital Management LP, Neuberger Berman Group LLC, Point72 Asset Management LP, Polen Capital Management LLC, Renaissance Technologies LLC, Soros Fund Management LLC, and 10 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →